

Resource Summary Report

Generated by ASWG on Aug 10, 2026

Purified (azide-free) anti-TDP43 Phospho (Ser409/410)

RRID:AB_2564934

Type: Antibody

Proper Citation

BioLegend Cat# 829901, RRID:AB_2564934

Antibody Information

URL: http://antibodyregistry.org/AB_2564934

Proper Citation: BioLegend Cat# 829901, RRID:AB_2564934

Target Antigen: TDP43 Phospho Ser409/410

Host Organism: Rat

Clonality: monoclonal

Comments: Applications: WB, IHC, ICC, ELISA

Info: Independent validation by the NYU Lagone was performed for: IHC. This antibody was found to have the following characteristics: Functional in human:TRUE, NonFunctional in human:FALSE, Functional in animal:FALSE, NonFunctional in animal:FALSE

Antibody Name: Purified (azide-free) anti-TDP43 Phospho (Ser409/410)

Description: This monoclonal targets TDP43 Phospho Ser409/410

Target Organism: rat, human

Clone ID: Clone 1D3/TDP-43

Antibody ID: AB_2564934

Vendor: BioLegend

Catalog Number: 829901

Record Creation Time: 20250819T225823+0000

Record Last Update: 20250820T035320+0000

Ratings and Alerts

- Independent validation by the NYU Lagone was performed for: IHC. This antibody was found to have the following characteristics: Functional in human:TRUE, NonFunctional in human:FALSE, Functional in animal:FALSE, NonFunctional in animal:FALSE - NYU Langone's Center for Biospecimen Research and Development <https://med.nyu.edu/research/scientific-cores-shared-resources/center-biospecimen-research-development>

No alerts have been found for Purified (azide-free) anti-TDP43 Phospho (Ser409/410).

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 11 mentions in open access literature.

Listed below are recent publications. The full list is available at [ASWG](#) .

Ramsey AC, et al. (2026) TGF- β signaling promotes astroglial activation and TDP-43 proteinopathy in organoid models of frontotemporal lobar degeneration. The Journal of clinical investigation, 136(14).

Guo L, et al. (2026) Defining RNA oligonucleotides that reverse deleterious phase transitions of RNA-binding proteins with prion-like domains. Molecular cell, 86(1), 114.

Selmanovic E, et al. (2025) Chronic traumatic encephalopathy neuropathologic change in the Late Effects of Traumatic Brain Injury project: Findings in a community autopsy cohort. Journal of neuropathology and experimental neurology, 84(12), 1174.

Dubey SK, et al. (2025) Aberrant nuclear pore complex degradation contributes to neurodegeneration in VCP disease. Neuron.

Shahidehpour RK, et al. (2025) Assessing Co-Localization of ITM2B With Alzheimer's Disease and Limbic-Predominant Age-Related TDP-43 Encephalopathy Neuropathologic Changes. Neuropathology : official journal of the Japanese Society of Neuropathology, 45(4), e70003.

Rummens J, et al. (2025) TDP-43 seeding induces cytoplasmic aggregation heterogeneity and nuclear loss of function of TDP-43. Neuron, 113(10), 1597.

Evangelista BA, et al. (2025) ALS-associated TDP-43 aggregates drive innate and adaptive immune cell activation. iScience, 28(6), 112648.

Alessandrini F, et al. (2025) TDP-43 dysfunction compromises UPF1-dependent mRNA metabolism in ALS. Neuron.

Lin NH, et al. (2023) Neuroprotective Effects of a Multi-Herbal Extract on Axonal and Synaptic Disruption in Vitro and Cognitive Impairment in Vivo. *Journal of Alzheimer's disease reports*, 7(1), 51.

Wani A, et al. (2021) Neuronal VCP loss of function recapitulates FTLTDP pathology. *Cell reports*, 36(3), 109399.

Gasset-Rosa F, et al. (2019) Cytoplasmic TDP-43 De-mixing Independent of Stress Granules Drives Inhibition of Nuclear Import, Loss of Nuclear TDP-43, and Cell Death. *Neuron*, 102(2), 339.